Background:In hospitalized patients with COVID-19, the dosing and timing of corticosteroids vary widely. Low-dose dexamethasone therapy reduces mortality in patients requiring respiratory support, but it remains unclear how to treat patients when this therapy fails. In critically ill patients, high-dose corticosteroids are often administered as salvage late in the disease course, whereas earlier administration may be more beneficial in preventing disease progression. Previous research has revealed that increased levels of various biomarkers are associated with mortality, and whole blood transcriptome sequencing has the ability to identify host factors predisposing to critical illness in patients with COVID-19.Objective:Our goal is to determine the most optimal dosing and timing of corticosteroid therapy and to provide a basis for personalized corticosteroid treatment regimens to reduce morbidity and mortality in hospitalized patients with COVID-19.Methods:This is a retrospective, observational, multicenter study that includes adult patients who were hospitalized due to COVID-19 in the Netherlands. We will use the differences in therapeutic strategies between hospitals (per protocol high-dose corticosteroids or not) over time to determine whether high-dose corticosteroids have an effect on the following outcome measures: mechanical ventilation or high-flow nasal cannula therapy, in-hospital mortality, and 28-day survival. We will also explore biomarker profiles in serum and bronchoalveolar lavage fluid and use whole blood transcriptome analysis to determine factors that influence the relationship between high-dose corticosteroids and outcome. Existing databases that contain routinely collected electronic data during ward and intensive care admissions, as well as existing biobanks, will be used. We will apply longitudinal modeling appropriate for each data structure to answer the research questions at hand.Results:As of April 2023, data have been collected for a total of 1500 patients, with data collection anticipated to be completed by December 2023. We expect the first results to be available in early 2024.Conclusions:This study protocol presents a strategy to investigate the effect of high-dose corticosteroids throughout the entire clinical course of hospitalized patients with COVID-19, from hospital admission to the ward or intensive care unit until hospital discharge. Moreover, our exploration of biomarker and gene expression profiles for targeted corticosteroid therapy represents a first step towards personalized COVID-19 corticosteroid treatment.Trial Registration:ClinicalTrials.gov NCT05403359; https://clinicaltrials.gov/ct2/show/NCT05403359International Registered Report Identifier (IRRID):DERR1-10.2196/48183
MULTIFILE
Vanuit Fontys Hogescholen wordt veel onderzoek gedaan, met name door onderzoekers van de verschillende lectoraten. Vanzelfsprekend worden er binnen deze onderzoeken veel data verzameld en verwerkt. Fontys onderschrijft het belang van zorgvuldige omgang met onderzoeksdata en vraagt daarom van onderzoekers dat zij hun Research Data Management (RDM) op orde hebben. Denk hierbij aan veilige opslag en duurzame toegankelijkheid van data. Maar ook (open access) publiceren en archiveren van onderzoeksdata maken onderdeel uit van RDM. Hoe je hier als onderzoeker invulling aan geeft kan soms best een zoektocht zijn, mede doordat nog niet iedereen even bekend is met het onderwerp RDM. Met dit boek hopen we onderzoekers binnen Fontys de belangrijkste informatie te bieden die nodig is om goed invulling te geven aan Research Data Management en daarbij ook te wijzen op de ondersteuning die op dit gebied voorhanden is.
